| |
| |
|
| Insider
Information: |
Torley Helen |
| Relationship: |
Director |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
683,004 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$30,539,335 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
683,004 |
|
|
| Total
Value |
$30,539,335 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -28.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Onyx Pharmaceuticals Inc |
ONXX |
EVP, Chief Commercial ... |
2013-10-01 |
0 |
2011-08-29 |
0 |
Premium* |
|
|
Halozyme Therapeutics Inc |
HALO |
|
2024-02-16 |
676,744 |
2014-09-16 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Quest Diagnostics Inc |
DGX |
Director |
2021-05-25 |
6,260 |
2018-05-15 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
169 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-29 |
4 |
AS |
$42.40 |
$424,020 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-30 |
4 |
AS |
$42.85 |
$428,540 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
PRESIDENT AND CEO |
• • – |
2023-08-31 |
4 |
AS |
$42.82 |
$428,170 |
D/D |
(10,000) |
623,666 |
0 |
% |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2014-09-16 |
4 |
B |
$8.92 |
$446,000 |
D/D |
50,000 |
50,000 |
2.81 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-09-03 |
4 |
D |
$123.62 |
$259,478 |
D/D |
(2,099) |
35,911 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-10-01 |
4 |
D |
$125.00 |
$3,571,875 |
D/D |
(28,575) |
0 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
EVP, Chief Commercial Officer |
• – – |
2013-10-01 |
4 |
D |
$125.00 |
$917,000 |
D/D |
(7,336) |
28,575 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2015-01-06 |
4 |
D |
$10.06 |
$119,905 |
D/D |
(11,919) |
68,081 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2015-12-31 |
4 |
D |
$17.33 |
$284,836 |
D/D |
(16,436) |
83,145 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2016-01-06 |
4 |
D |
$15.77 |
$184,288 |
D/D |
(11,686) |
101,459 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2016-02-06 |
4 |
D |
$7.90 |
$92,770 |
D/D |
(11,743) |
120,966 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2016-06-30 |
4 |
D |
$8.63 |
$60,790 |
D/D |
(7,044) |
127,422 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-09-01 |
4 |
D |
$32.00 |
$39,584 |
D/D |
(1,237) |
2,250 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-09-01 |
4 |
D |
$32.00 |
$72,000 |
D/D |
(2,250) |
0 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2018-01-06 |
4 |
D |
$19.46 |
$226,690 |
D/D |
(11,649) |
262,510 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2018-02-03 |
4 |
D |
$18.37 |
$442,919 |
D/D |
(24,111) |
293,886 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2018-02-06 |
4 |
D |
$18.25 |
$282,747 |
D/D |
(15,493) |
309,643 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2018-02-22 |
4 |
D |
$19.28 |
$376,172 |
D/D |
(19,511) |
329,486 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2019-02-03 |
4 |
D |
$16.12 |
$313,131 |
D/D |
(19,425) |
365,548 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2019-02-06 |
4 |
D |
$16.73 |
$243,371 |
D/D |
(14,547) |
382,251 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2019-02-14 |
4 |
D |
$16.54 |
$235,596 |
D/D |
(14,244) |
396,737 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2019-02-22 |
4 |
D |
$16.81 |
$327,980 |
D/D |
(19,511) |
416,580 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2020-02-03 |
4 |
D |
$19.21 |
$382,471 |
D/D |
(19,910) |
439,657 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2020-02-12 |
4 |
D |
$20.00 |
$325,180 |
D/D |
(16,259) |
456,193 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
President and CEO |
• • – |
2020-02-14 |
4 |
D |
$21.10 |
$300,548 |
D/D |
(14,244) |
470,679 |
0 |
- |
|
169 Records found
|
|
Page 3 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
